304 related articles for article (PubMed ID: 28637924)
1. VP4- and VP7-specific antibodies mediate heterotypic immunity to rotavirus in humans.
Nair N; Feng N; Blum LK; Sanyal M; Ding S; Jiang B; Sen A; Morton JM; He XS; Robinson WH; Greenberg HB
Sci Transl Med; 2017 Jun; 9(395):. PubMed ID: 28637924
[TBL] [Abstract][Full Text] [Related]
2. Reverse Genetics Approach for Developing Rotavirus Vaccine Candidates Carrying VP4 and VP7 Genes Cloned from Clinical Isolates of Human Rotavirus.
Kanai Y; Onishi M; Kawagishi T; Pannacha P; Nurdin JA; Nouda R; Yamasaki M; Lusiany T; Khamrin P; Okitsu S; Hayakawa S; Ebina H; Ushijima H; Kobayashi T
J Virol; 2020 Dec; 95(2):. PubMed ID: 33087468
[TBL] [Abstract][Full Text] [Related]
3. Rotavirus-neutralizing antibodies inhibit virus binding to integrins alpha 2 beta 1 and alpha 4 beta 1.
Fleming FE; Graham KL; Taniguchi K; Takada Y; Coulson BS
Arch Virol; 2007; 152(6):1087-101. PubMed ID: 17318737
[TBL] [Abstract][Full Text] [Related]
4. Antibodies to rotavirus outer capsid glycoprotein VP7 neutralize infectivity by inhibiting virion decapsidation.
Ludert JE; Ruiz MC; Hidalgo C; Liprandi F
J Virol; 2002 Jul; 76(13):6643-51. PubMed ID: 12050377
[TBL] [Abstract][Full Text] [Related]
5. Homotypic and heterotypic serum neutralizing antibody response to rotavirus proteins following natural primary infection and reinfection in children.
Gorrell RJ; Bishop RF
J Med Virol; 1999 Feb; 57(2):204-11. PubMed ID: 9892409
[TBL] [Abstract][Full Text] [Related]
6. Expression and characterization of a novel truncated rotavirus VP4 for the development of a recombinant rotavirus vaccine.
Li Y; Xue M; Yu L; Luo G; Yang H; Jia L; Zeng Y; Li T; Ge S; Xia N
Vaccine; 2018 Apr; 36(16):2086-2092. PubMed ID: 29555220
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of the immunogenicity of monovalent and multivalent rotavirus immunogens.
Mi K; Ou X; Guo L; Ye J; Wu J; Yi S; Niu X; Sun X; Li H; Sun M
PLoS One; 2017; 12(2):e0172156. PubMed ID: 28207817
[TBL] [Abstract][Full Text] [Related]
8. Homotypic and heterotypic serum isotype-specific antibody responses to rotavirus nonstructural protein 4 and viral protein (VP) 4, VP6, and VP7 in infants who received selected live oral rotavirus vaccines.
Yuan L; Ishida S; Honma S; Patton JT; Hodgins DC; Kapikian AZ; Hoshino Y
J Infect Dis; 2004 May; 189(10):1833-45. PubMed ID: 15122520
[TBL] [Abstract][Full Text] [Related]
9. VP4 and VP7 typing using monoclonal antibodies.
Coulson BS
Arch Virol Suppl; 1996; 12():113-8. PubMed ID: 9015108
[TBL] [Abstract][Full Text] [Related]
10. Neutralization of rotavirus and recognition of immunologically important epitopes on VP4 and VP7 by human IgA.
Johansen K; Svensson L
Arch Virol; 1997; 142(7):1491-8. PubMed ID: 9267458
[TBL] [Abstract][Full Text] [Related]
11. Recombinant bivalent subunit vaccine combining truncated VP4 from P[7] and P[23] induces protective immunity against prevalent porcine rotaviruses.
Tang X; Li S; Zhou J; Bian X; Wang J; Han N; Zhu X; Tao R; Wang W; Sun M; Li P; Zhang X; Li B
J Virol; 2024 May; 98(5):e0021224. PubMed ID: 38591886
[TBL] [Abstract][Full Text] [Related]
12. Serotype specificity of the neutralizing-antibody response induced by the individual surface proteins of rotavirus in natural infections of young children.
Menchaca G; Padilla-Noriega L; Méndez-Toss M; Contreras JF; Puerto FI; Guiscafré H; Mota F; Herrera I; Cedillo R; Muñoz O; Ward R; Hoshino Y; López S; Arias CF
Clin Diagn Lab Immunol; 1998 May; 5(3):328-34. PubMed ID: 9605987
[TBL] [Abstract][Full Text] [Related]
13. Identification of VP7 epitopes associated with protection against human rotavirus illness or shedding in volunteers.
Green KY; Kapikian AZ
J Virol; 1992 Jan; 66(1):548-53. PubMed ID: 1370092
[TBL] [Abstract][Full Text] [Related]
14. Human VP8* mAbs neutralize rotavirus selectively in human intestinal epithelial cells.
Feng N; Hu L; Ding S; Sanyal M; Zhao B; Sankaran B; Ramani S; McNeal M; Yasukawa LL; Song Y; Prasad BVV; Greenberg HB
J Clin Invest; 2019 Aug; 129(9):3839-3851. PubMed ID: 31403468
[TBL] [Abstract][Full Text] [Related]
15. Antibodies to the trypsin cleavage peptide VP8 neutralize rotavirus by inhibiting binding of virions to target cells in culture.
Ruggeri FM; Greenberg HB
J Virol; 1991 May; 65(5):2211-9. PubMed ID: 1850007
[TBL] [Abstract][Full Text] [Related]
16. Antibody response to serotype-specific and cross-reactive neutralization epitopes on VP4 and VP7 after rotavirus infection or vaccination.
Taniguchi K; Urasawa T; Kobayashi N; Ahmed MU; Adachi N; Chiba S; Urasawa S
J Clin Microbiol; 1991 Mar; 29(3):483-7. PubMed ID: 1709946
[TBL] [Abstract][Full Text] [Related]
17. Genetic diversity of G1P[8] rotavirus VP7 and VP8* antigens in Finland over a 20-year period: No evidence for selection pressure by universal mass vaccination with RotaTeq® vaccine.
Hemming M; Vesikari T
Infect Genet Evol; 2013 Oct; 19():51-8. PubMed ID: 23831933
[TBL] [Abstract][Full Text] [Related]
18. Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to the heterotypic neutralization domain of VP7 and the VP8 fragment of VP4.
Matsui SM; Offit PA; Vo PT; Mackow ER; Benfield DA; Shaw RD; Padilla-Noriega L; Greenberg HB
J Clin Microbiol; 1989 Apr; 27(4):780-2. PubMed ID: 2470774
[TBL] [Abstract][Full Text] [Related]
19. Homotypic protection against rotavirus-induced diarrhea in infant mice breast-fed by dams immunized with the recombinant VP8* subunit of the VP4 capsid protein.
Gil MT; de Souza CO; Asensi M; Buesa J
Viral Immunol; 2000; 13(2):187-200. PubMed ID: 10892999
[TBL] [Abstract][Full Text] [Related]
20. Production of reassortant viruses containing human rotavirus VP4 and SA11 VP7 for measuring neutralizing antibody following natural infection.
Gorrell RJ; Bishop RF
Clin Diagn Lab Immunol; 1997 Sep; 4(5):509-14. PubMed ID: 9302196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
